Hims & Hers: The Brand Is Being Put To The Test (Downgrade)

2025-06-05 09:05:35 ET

Summary

• Hims & Hers Health, Inc. has seen massive success, aided by the growing use of GLP-1 drugs. The company outlined an ambitious $6.5 billion 2030 revenue target.
• Risks are rising. FDA's decision to determine the GLP-1 shortage as resolved makes Hims & Hers' industry positioning uncertain, despite the Novo Nordisk partnership.
• Rising competition is putting Hims & Hers' brand moat to test. Signals suggest that the brand's momentum is slowing down cautiously.
• The higher valuation isn't attractive anymore. I estimate HIMS to have a 23% upside to $69.7 if the company successfully fades risks.

Hims & Hers Health, Inc. ( HIMS ) has reached a new level as GLP-1 growth has surged. Yet, the telehealth platform’s growth story comes with increasing risks, touching Hims & Hers’ GLP-1 positioning but also the company’s operations as a whole. While rapid growth is set to continue, Hims & Hers' much more expensive stock valuation doesn't present an attractive risk-to-reward investment anymore – a lot of growth is already priced in....

Read the full article on Seeking Alpha

For further details see: